Results 91 to 100 of about 4,421 (195)

Real-life experience of patients starting insulin degludec. A multicenter analysis of 1064 subjects from the German/Austrian DPV registry

, 2017
Background The long-acting insulin analogue degludec is a therapeutic option for patients with type 1 (T1D) or type 2 diabetes (T2D). Aim of this analysis was to investigate differences in clinical characteristics of patients before and after initiating
Zindel, Volker, Dunstheimer, Desirée, Florian Kopp, Kopp, Florian, Merger, Sigrun, Holl, Reinhard W., Sigrun Merger, Katja Gollisch, Reinhard W. Holl, Barbara Bohn, Dunstheimer, Desirée P. A., Volker Zindel, Zimmermann, Artur, Christian Wagner, Desirée Dunstheimer, Wagner, Christian, Bohn, Barbara, Artur Zimmermann, Gollisch, Katja   +18 more
core   +1 more source

Better glycaemic control with once-weekly insulin icodec versus once-daily insulin degludec in adults with insulin-naive type 2 diabetes (ONWARDS 3)

, 2023
International audienceBackground and aims: Efficacy and safety of once-weekly insulin icodec (icodec) versus once-daily insulin degludec (degludec) in adults with insulin-naïve type 2 diabetes were examined in ONWARDS 3, a 26-week, randomised, double ...
Desouza, C., Vinther, S., Lingvay, I., Vianna, A., Asong, M., Mu, Y., Vilsbøll, T., Gourdy, Pierre, Kar, S.   +8 more
core   +1 more source

Basal insulin degludec - liraglutide fixed ratio combination (Xultophy(R))

, 2018
peer reviewedXultophy(R) (IDegLira) is a fixed ratio combination of basal insulin degludec and glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide.
Scheen, André, Mathieu, Chantal
core   +1 more source

Use of insulin degludec, a new basal insulin with an ultra-long duration of action, in basal-bolus therapy in type 1 and type 2 diabetes.

, 2013
International audienceInsulin degludec is a new basal insulin analogue with an ultra-long duration of action that provides a flat and stable action profile with a duration of action greater than 42hours. Two clinical trials comparing insulin degludec and
Marre, Michel, Kerlan, Véronique, Gouet, Didier, Renard, Eric   +3 more
core   +1 more source

Insulin degludec: Overview of a novel ultra long-acting basal insulin

, 2013
All the basal insulin products currently available have suboptimal pharmacokinetic (PK) properties, with none reliably providing a reproducible and peakless pharmacodynamic (PD) effect that endures over 24 h from once-daily dosing.
Harris, S, Gough, Stephen, Gough, SCL, Davies, M, Gough, SC, Woo, V   +5 more
core   +1 more source

Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England

BMJ Open Diabetes Research & Care
Introduction The prevalence of people with type 2 diabetes (T2D) on basal insulin (BI) is rising to improve glucose control and minimize complications.
Iskandar Idris, Amar Puttanna, Karen Palmer, Fatemeh Saberi Hosnijeh, Neil Holden, Aymeric Mahieu, Onyinye Diribe, Charlie Nicholls, Xiaocong Li Marston, Nick Denholm   +9 more
doaj   +1 more source

Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India

Diabetes, Metabolic Syndrome and Obesity, 2014
Binayak Sinha,1 Kalyan Kumar Gangopadhyay,2 Samit Ghosal31Department of Endocrinology, AMRI Hospital, 2Department of Endocrinology, Fortis and Peerless Hospital, 3Nightingale Hospital, Kolkata, IndiaAbstract: Insulin therapy is not without side effects ...
Sinha B, Gangopadhyay KK, Ghosal S
doaj  

Sensor-Derived Glycemic Metrics in Women with Type 1 Diabetes Using Insulin Degludec Versus Other Basal Insulin Analogs During Pregnancy—A Post Hoc Analysis of the CopenFast Trial

Women's Health Reports
Aim: To explore sensor-derived glycemic metrics during pregnancy in women with type 1 diabetes using insulin degludec or other basal insulin analogs.
Julie C. Søholm, Sidse K. Nørgaard, Kirsten Nørgaard, Tine D. Clausen, Peter Damm, Elisabeth R. Mathiesen, Lene Ringholm   +6 more
doaj   +1 more source

Insulin Degludec [PDF]

, 2020
openaire   +1 more source

Insulin degludec in pregestational diabetes: evidence and perspectives

Archives of Medical Science – Atherosclerotic Diseases
Pregestational diabetes is described when a woman with diabetes before the onset of pregnancy becomes pregnant and consequently she is vulnerable to higher risk for adverse outcomes in the embryo/foetus. Strict glycaemic control, with minimal glucose variability, starting from before conception and maintained throughout pregnancy decreases ...
Papaetis, Georgios S., Mikellidis, Konstantinos C.   +1 more
openaire   +2 more sources